Vermont is currently home to 197 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Burlington, Bennington, Berlin and White River Junction. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
Accelerated Pulmonary Rehabilitation in the Preoperative Period
NCT06432972
Recruiting
This proposed project will be a single arm, non-masked study. Participants who are actively smoking with a diagnosis of a new lung nodule, either confirmed or suspicious for lung cancer, with a plan for lung cancer treatment with or without surgical resection will be recruited from the University of Vermont Medical Center (UVMMC)pulmonary, cardiothoracic surgery, and Lung Multidisciplinary Clinic (LMDC). All patients will be enrolled in prehab and offered smoking cessation therapy. The acceptabi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Neuropsychiatric Associates, Plc, Woodstock, Vermont
Conditions: Treatment Resistant Depression
Register for Updates
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
NCT06692894
Recruiting
Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: University of Vermont, Burlington, Vermont
Conditions: Myelodysplastic Syndromes, Adult
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Vermont Oxford Network Very Low Birth Weight Database
NCT01825499
Recruiting
Vermont Oxford Network maintains a database for live born infants \<=1500 grams or \<=29 weeks gestational age who are born at participating hospitals or admitted to them within 28 days of birth, regardless of where in the hospital the infant receives care.
Gender:
ALL
Ages:
28 days and below
Trial Updated:
11/19/2024
Locations: Vermont Oxford Network, Burlington, Vermont
Conditions: Neonatology
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/05/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Rheumatic Joint Disease
Register for Updates
Protocol for Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens from Children and Young Adults with Hematologic Malignancy
NCT04968834
Recruiting
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. U... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
11/04/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
Register for Updates
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
NCT04687358
Recruiting
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
10/18/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Recurrent Pericarditis
Register for Updates
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT04851613
Recruiting
Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: University of Vermont, Burlington, Vermont
Conditions: Breast Cancer
Register for Updates
Flat Dose Vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT04779554
Recruiting
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Peritoneal Carcinomatosis
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: University of Vermont Medical Center, Burlington, Vermont
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates